Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Wancai Yang

Wancai Yang

University of Illinois at Chicago USA

Yonghua Bao

Yonghua Bao

Jining Medical University China

M Davenport

M Davenport

Salford Royal NHS Foundation Trust UK

Yeng S Ang

Yeng S Ang

Salford Royal University Hospital UK

Wolfgang B Fischer

Wolfgang B Fischer

National Yang-Ming University Taiwan

Sepehr Soleymani

Sepehr Soleymani

Pasteur Institute of Iran Iran

Şükrü Tüzmen

Şükrü Tüzmen

Eastern Mediterranean University Turkey

Nima Sanadgol

Nima Sanadgol

University of Zabol Iran

Molecular Markers 2018

About Conference

ME Conferences cordially invites all the participants across the globe to attend the “International Conference on Molecular Markers and Cancer Therapeutics” during October 08-09, 2018 Dubai, the largest and most populous city in the United Arab Emirates (UAE). Molecular Markers 2018 is organized around the theme: “Clinical Advancements in Discovery of Molecular Markers in Cancer Treatment”.

This gathering is a rostrum that brings and offers aggregate learning and research investigations in Molecular Markers. In the current years, the information about Cancer Therapeutics has expanded to a great extent giving a colossal potential for enhancing the administration of malignancy patients by enhancing the exactness of detection and viability of treatment. Most recent innovative progressions have empowered the examination of numerous Biomarkers and have re-established enthusiasm for developing new Molecular Markers. Every such advancement can be evidenced in this Molecular Markers 2018.



With members from around the world focused on research in Molecular Markers and Cancer Therapeutics, and its advances, it is a great opportunity to update to latest regulatory guidelines and approvals in Molecular Marker research; Experience live case studies from pioneers who developed & created a Biomarker; Best platform to promote collaborative research & initiate long-lasting business partnerships and a World-class platform to Exhibit the products and services. World-renowned speakers, the most recent techniques, developments and the newest updates in Cancer Therapeutics are hallmarks of this conference.


  • Oncologists
  • Molecular Biologists
  • Cell Biologists
  • Pathologists
  • Haematologists
  • Immunologists
  • Clinical Researchers
  • Nursing
  • Cancer Researchers
  • Scientists
  • Young Researchers
  • Molecular Marker Associations and Societies
  • Cancer Therapeutics Institutes
  • Training Institutes
  • Business Entrepreneurs
  • Software developing companies
  • Manufacturing Medical Devices Companies
  • Data Management Companies
  • Pharmaceutical Companies
  • Diagnostics Companies



Session &Tracks

Track 1: Molecular Markers

A molecular marker is a DNA arrangement in the genome which can be found and recognized. DNA, for instance, is a molecular marker containing information about hereditary disorders, family history and the transformative history of life. Genetic markers are utilized to analyze the autosomal recessive hereditary disorder cystic fibrosis, phylogenetic and DNA Barcoding. Further, living things are known to shed one of the kind chemicals, including DNA, into the environment as proof of their essence in a specific area. Other organic markers, similar to proteins, are utilized as a part of symptomatic tests for complex neurodegenerative disorders.


Track 2: Immuno-Oncology Biomarkers

The achievements in the utilization of immunotherapy to treat disease have prompted a multiplicity of new compounds being developed. Novel clinical-grade biomarkers are expected to direct the decision of these specialists to acquire the maximal probability of patient advantage. Predictive biomarkers for immunotherapy vary from the traditional biomarkers utilized for focused treatments: the unpredictability of the insusceptible response and tumor biology requires a more comprehensive approach than the utilization of a single analyte biomarker. The circumstance for immuno-oncology (IO) drugs that follow up on the host immune system is that it constitutes the "treatment" for fighting the tumor. The objective of disease immunotherapy is to initiate or reiterate a self-maintaining cycle of tumor immunity empowering it to enhance and engender an anticancer response. In this way, there is a requirement for biomarkers to distinguish the detours and the underlying biology at the individual patient level to manage a suitable therapeutic intervention.


Track 3: Neurological Biomarkers

The major aim of biomarker research in neurology has been to provide clinicians with biochemical and neuroimaging tools that enable accurate diagnosis before widespread neuronal death has occurred. Such biomarkers are a prerequisite for effective secondary prevention strategies, and may also facilitate therapeutics by (i) providing measures of desired biochemical effects of a compound in the preclinical drug discovery phase; (ii) allowing the specific inclusion of early cases that are very likely to develop the disease of interest; and (iii) identifying subgroups of patients according to biochemical patterns to individualize treatment. In addition, biomarker changes during disease progression and correlations between different biomarkers may provide clues on pathogenic mechanisms. Several studies have already been conducted, most of them using the Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers total and phosphorylated tau proteins that reflect the axonal component of the disease and the 42-amino acid fragment of amyloid β (Aβ42) that reflects plaque pathology in the brain to diagnose AD before onset of dementia.


Track 4: Cardiovascular Biomarkers

Clinicians have utilized additional tools to help clinical evaluation and to upgrade their capacity to distinguish the "vulnerable" patient in danger for CVD wherein biomarkers are one such tool to better recognize high-risk people, to analyze ailment conditions expeditiously and precisely, and to viably forecast and treat patients with the disease. In a patient presenting to the emergency department with an acute coronary syndrome, a biomarker may differentiate patients with an acute myocardial infarction (MI) from those with unstable angina, acute pulmonary embolism or an aortic dissection in an opportune manner to encourage targeted management.


Track 5: Clinical and Translational Biomarkers

Translational Medicine utilizes a patient-driven way to deal with drug development and is a consequence of the practical application of the changes made in biomarker revelation in the era of personalized medicine(PM). Basic to the translational medicine is the transformation of insights of knowledge from pre-clinical research into early clinical trials. Likewise, TM fosters progressing assessment of clinical biomarker data to both illuminate the following phase of trials and to give feedback into extra pre-clinical trials. Since pre-clinical models are known to be defective at anticipating the human response, the translational medicine groups must utilize biomarkers to quantify however much data as they can in the clinic. This interpretation of learning between pre-clinical and clinical research is important to outline and run successful clinical trials and ultimately deliver effective medicines to patients.


Track 6: Biomarkers in Personalized Medicine

Biomarkers are of progressively high significance in medicine, especially in the domain of 'personalized medicine'. They are profitable for predicting prognosis and dosage determination. Besides, they might be useful in recognizing therapeutic and adverse responses and in understanding stratification in light of adequacy or safety prediction. Despite the fact that utilization of the term personalized medicine is regularly constrained to the recognizable proof of the optimal drug and the optimal dose for a subgroup of patients, current personalized medicine applications are significantly more expansive, and might incorporate circumstances of withholding treatment, preventive interventions, or focused on treatment alternatives for individual patients.


Track 7: Biomarkers in Cell Biology

In cell biology, a biomarker is a molecule that permits the detection and isolation of a specific cell type. In genetics, a biomarker is a DNA sequence that causes disease or is related to susceptibility to the ailments. They can be utilized to make hereditary maps of whatever creature is being examined. Cell biomarkers enable cells to be separated, arranged, measured and portrayed by their morphology and physiology. Cell biomarkers are utilized as a part of both clinical and laboratory settings and can segregate between substantial samples of cells based on their antigens. An example of a cell biomarker sorting technique is Fluorescent-activated cell sorting.


Track 8: Biomarkers in Medicine

Biomarkers in medicine have increased thorough logical and clinical intrigue. Biomarker characterized as the modification in the constituents of tissues or body fluids give an effective way to deal with understanding the range of chronic illness with application in no less than 5 areas like screening, diagnosis, prognostication, prediction of illness recurrence and restorative monitoring. In this way, biomarkers are biological markers of diseases that can be estimated either in vivo by biomedical imaging or in vitro by laboratory techniques. In medicine, a biomarker can be a traceable substance that is brought into a living being as a way to look at organ function or different aspects of wellbeing.


Track 9: Mapping of Genetic Markers

Molecular mapping helps in identifying the location of specific markers inside the genome. There are two kinds of maps. To start with is a physical map, which identifies the chromosome and area on it. Furthermore, there is a linkage map recognizes how specific genes are connected to different genes on a chromosome. In some organisms, maps appeared to be "full" of loci of known phenotypic impact and estimations demonstrated that the chromosomal intervals between genes needed to contain DNA. These gaps couldn't be mapped by linkage analysis, on the grounds that there were no markers in those regions. A molecular marker is a site of heterozygosity for some sort of DNA variety. Such a "DNA locus," when heterozygous, can be utilized as a part of mapping analysis.


Track 10: Biochemical Markers

Biochemical markers recognize variety at the gene level. Biochemical markers are for the most part the protein marker. These depend on the variation in the grouping of amino acids in a protein molecule. The essential protein marker is alloenzyme. Alloenzymes are various types of an enzyme that are coded by various alleles at a similar locus and these alloenzymes vary from species to species.


Track 11: Discovery and Development of Immuno-Oncology Biomarkers

The advancements, for example, mass spectrometry, protein and DNA clusters, joined with our comprehension of the human genome, have prompted recharged enthusiasm for the revelation of novel disease biomarkers. Each time of biomarker disclosure is by all accounts related intimately with the development of another and capable scientific innovation. The previous decade has seen an amazing development in the field of extensive scale and high-throughput science, which has added to a period of innovation improvement. The consummation of various genome-sequencing ventures, the disclosure of oncogenes and tumour-silencer qualities, and on-going advances in genomic and proteomic innovations, together with intense bioinformatics instruments, will have an immediate and significant effect in transit the scan for disease biomarkers .Tumour biomarker disclosure and improvement falls into five applied stages: preclinical exploratory investigations; clinical test and approval; review longitudinal examinations; imminent screening; and randomized control trials. Prostate-particular antigen (PSA [KLK3]), outstanding amongst other biomarkers discovered.




Track 12: Cancer Causes and Diagnosis

Cancer is the uncontrolled development of unusual cells anywhere in a body. The DNA inside a cell is bundled into endless characteristics, every one of which contains an arrangement of principles urging the cell what capacities to perform, and besides how to create and disengage. A family history of specific cancer can be an indication of a possible procured warning.

The Cancer Diagnostics Market consolidates various parts of treatment and is partitioned on basis of Technology, Application, and Region. Oncology depends upon logical instruments like biopsy or ejection of bits of the growing tissue and analyzing it under the magnifying lens. Other symptomatic devices include endoscopy for the gastrointestinal tract, imaging concentrates like X-bars, CT analyzing, MRI checking, ultrasound and other radiological methodologies, Scintigraphy, Single Photon Emission Computed Tomography, Positron Emission Tomography and nuclear medicine so on.


Track 13: Cancer Biomarkers and Therapeutics

Cancer biomarkers are the quantifiable molecular changes to either cancerous or normal tissues of patients. A reliable biomarker can be utilized for cancer analysis, hazard and prognosis evaluations, and for the observation of treatment effectiveness. One of the cancer biomarkers is the Warburg effect which is the shift of mitochondrial vitality generation to a glycolysis dependent metabolism that gives vitality to cells as well as produces moderate building materials for cancer cells to develop.

Cancer Therapeutics exploits the vulnerabilities of disease cells by finding novel and creative small-molecule drugs for the customized treatment of cancer. It likewise creates biomarkers to affirm the adequacy of molecularly focused on treatments. The need of Cancer Therapeutics is to handle the challenge of tumor heterogeneity, malignancy advancement and resistance to drug treatments.


Track 14: Imaging Biomarkers

Imaging biomarkers (IBs) are fundamental to the normal administration of patients with cancer. A quantitative imaging biomarker (QIB) is a target characteristic got from an in vivo image estimated on a proportion or interval scale as markers of typical organic procedures, pathogenic procedures or a reaction to a therapeutic intervention. The benefit of QIB's over subjective imaging biomarkers is that they are more qualified to be utilized for follow-up of patients or in clinical trials. Other CT, MRI, PET, and ultrasonography biomarkers are used extensively in cancer research and drug development. Imaging biomarkers have the stand-out favorable position that they examine the right disease focus, for instance, an infarct or tumor. Furthermore, they are non-invasive and allow follow-up especially where imaging modalities without ionizing radiation are used.


Track 15: Next-Generation Sequencing for Disease Biomarkers

Next-generation sequencing (NGS) is starting to give effective experiences into genetic mutations and molecular networks are hidden ailment for a wide set of genes. NGS advances guarantee to change various areas in clinical practice, including the approval and examination of sequencing-based biomarkers, a tool progressively pertinent for diagnosis in different disease areas and for the determination and checking of therapeutic treatments. An entire clinical viewpoint keeps on depending on different sorts of testing, in light of imaging or on the investigation of molecular biomarkers. Be that as it may, in this is an extra quality of NGS platforms, which offer versatility to look at various cell properties beyond the determination of genomic sequence alone. The scope of extra applications is exceptionally wide, including transcriptomic profiling, examination of alternative spliced forms and profiling of small RNA populations.


Market Analysis


ME Conferences graciously welcomes all the participants across the World to attend “International Conference on Molecular Markers and Cancer Therapeutics” during October 8-9, 2018 at Dubai, UAE. This gathering gives a firm stage to researchers, Doctors, specialists, neurologists, chiefs of different organizations, industry experts, and students in the field of Molecular Markers and Cancer Therapeutics. We also take immense pleasure in welcoming various professionals from different countries all over the globe.

ME Conferences organizes a 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in the Middle East, Asia, Europe, and the USA with support from 1000 more scientific societies and publishes 700+ Open access journals which contain over 30000 eminent personalities, reputed scientists as editorial board members.


Cancer is the uncontrolled growth of abnormal cells in the body. Cancer is not limited by gender, age, or ethnicity and has no physical barriers within the body. Through the “International Conference on Molecular Markers and Cancer Therapeutics,” we provide a vast platform for people in various fields to discuss in deep about the subject.  

New genomic and proteomic technologies have led to important therapeutic advances in oncology. The discovery of molecular prognostic markers to classify an individual patient’s risk of disease events and predictive markers to classify response to specific treatment options are used to guide the selection of treatment and identify targets for the development of new molecular-targeted therapies.


Molecular Markers 2018 is going to be held in Dubai, United Arab Emirates (UAE). Public hospitals in Dubai were first built in the late 1950s and continued to grow with public health initiatives. There are now 28 hospitals in Dubai, 6 public and 22 private, with 3 more major hospitals scheduled to be built by 2025. Cancer Therapeutics research is basically going ahead in Asian nations close to Dubai, so it is a reasonable goal for Oncology and Cancer gatherings.


Molecular biomarker research is broadly empowered everywhere throughout the world and the specialists from different cross orders like oncology, pathology, proteomics, genomics, pharmacologists, specialists, clinicians and innovation amplification businesses working in the field of biomarkers.







In Dubai:

  • Ernakulam Pravassi Welfare Association
  • Ananthapuram Non Residents Association
  • Venjaramoodu Non Resident Malayalee
  • Dubai Charity Association
  • Dubai Chamber Of Commerce & Industry
  • Saudi Cancer Society, Dubai, UAE.
  • Saudi oncology society and Saudi urology association, Dubai, UAE.
  • Saudi Arabia Cancer Organizations and Resources, Dubai, UAE.


  • Emirates Medical Association
  • Emirates Society of Haematology
  • Dubai Health Authority
  • Middle East cancer consortium


  • American Association for Cancer Research, USA.
  • American Brain Tumor Association, USA.
  • American Cancer Society, USA.
  • American Society for Radiation Oncology, USA.
  • American Society of Clinical Oncology, USA.
  • European Association for Cancer Research, Europe.
  • Association for International Cancer Research AICR, UK.
  • Association of European Cancer Leagues, Europe.
  • European Oncology Nursing Society, Europe.
  • European Society for Medical Oncology, Europe.
  • European Society of Gynaecological Oncology, Europe.
  • European Society of Surgical Oncology, Europe.
  • Acoustic Neuroma Association of Australia, Australia.
  • Clinical Oncological Society of Australia, Australia.
  • Australian Society of Gynecologic Oncologists, Australia.
  • Asian Society of Gynecologic Oncology, Asian.
  • Asian Society for Neuro-Oncology, Asian.
  • Saudi Cancer Society, Dubai, UAE.
  • Saudi oncology society and Saudi urology association, Dubai, UAE.
  • Saudi Arabia Cancer Organizations and Resources, Dubai, UAE.
  • Malaysian Oncology Society, Malaysia.
  • Malaysian Society of Paediatric Haematology and Oncology, Malaysia.


In Dubai:

  • Murdoch University, Dubai
  • Heriot-Watt University Dubai Campus
  • Modul University Dubai
  • Middlesex University Dubai
  • Hamdan Bin Mohammed  Smart University
  • Curtin University Dubai
  • University of South Wales Dubai
  • Emirates Aviation University


  • Al Ghurair University (AGU)
  • University of Dubai (UD)
  • Zayed University
  • American University in Dubai (AUD)
  • British University in Dubai (BUiD)
  • American University in the Emirates (AUE)


  • University of Toronto, Canada
  • Washington University in St. Louis
  • National University of Singapore (NUS), Singapore
  • University Of Florida
  • Oregon Health and Science University
  • Knight Cancer Institute
  • University Of Western Sydney, Australia
  • University of Melbourne
  • Monash University, Australia
  • University of Milan, Italy
  • The University of Auckland, NZ
  • University Of Zurich
  • National Taiwan University
  • The University of Manchester, UK
  • Pondicherry University, India
  • Osaka University, Japan



  • Royal Cancer Hospital
  • King’s College Hospital
  • Leiden University Medical Centre
  • Clatter bridge Centre for Oncology
  • Northampton General Hospital
  • Cambridge University Hospitals
  • University Hospital Southampton
  • Central Manchester University Hospitals


The global biomarkers market has grown to $39.4 billion in 2014 from $29.3 billion in 2013. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 billion in 2020.

The total cost of cancer therapeutics and medicines used in supportive care– measured at the ex-manufacturer price level before the application of rebates or other price concessions – reached $107 billion in 2015, representing an increase in constant dollars of 11.5% over the prior year. Annual global growth in the oncology drug market is expected to be 7.5 – 10.5 % through 2020, reaching $150 billion. Wider utilization of new products—especially immunotherapies—will drive much of the growth, offset by reduced use of some existing treatments with inferior clinical outcomes.

The global market for biologic cancer treatment totaled about $51.2 billion in 2014 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019. It includes current issues and trends affecting the industry, costs, and factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.


Related Conferences: Cancer Events| Oncology Meetings | Molecular Markers Conferences | Cancer Research Events


Related Societies:

American Society of Clinical Oncology, European Society For Medical Oncology, International Agency for Research on Cancer, International Society of Geriatric Oncology, International Society of Paediatric Oncology, European Society of Breast Cancer Specialists, European Society of Surgical Oncology

Other Related Societies:

USA: American Cancer Society, American Childhood Cancer Organisation, American Society for Blood & Marrow Transplantation, American Society for Colposcopy and Cervical Pathology, American Society of Clinical Oncology, American Society of Haematology, American Society of Paediatric Oncology, American Association for Cancer Research, American Breast Cancer Foundation, Haematology/Oncology Pharmacy Association, International Agency for Research on Cancer (IARC)

Europe: European Cancer Organisation, European Cervical Cancer Association , European Head and Neck cancer Awareness, European Haematology Association, European society of molecular imaging, UK Oncology Nursing Society, United Kingdom Association of Cancer Registries, Childhood Cancer Research Group Cancer Focus BASO, European Society of Oncologic Imaging, European Association for Cancer Research, European Society of Surgical Oncology, European Society for Medical Oncology, UK Oncology Nursing Children’s Cancer and Leukaemia Group Society,  EFB European Federation of BiotechnologyEuropean Diagnostic Manufacturers AssociationEuropean Society of Pathology  ICGEB, International Centre for Genetic Engineering and Biotechnology

Asia Pacific: Chinese Society for Cell Biology (CSCB), Chinese Society of Biochemistry and Molecular Biology, The Hong Kong Society of Biochemistry and Molecular Biology, The Chinese Biological Investigator Society, Australian Society for Biochemistry and Molecular Biology, Korean Society for Biochemistry and Molecular Biology (KSBMB), The Federation of Asian and Oceanian Biochemists (FAOB)Japan Society for Molecular Science, The Genetics Society of Japan (GSJ), Fungal Molecular Biology Society of Japan, Association for Molecular Pathology (AMP), Molecular Pathology Association of India (MPAI).

Middle East : Mazzara – Emirates Association for Cancer Support, Angels of Mercy Cancer Society, Friends of Cancer Patients SocietyAssociation for Molecular Pathology, Thailand division of International Academy of Pathology, Taiwan Society of Pathology, Indonesian Association of Clinical Pathology and Laboratory Medicine, Romanian Society of Biochemistry and Molecular Biology, Romanian Society of Human Genomics, The Malaysian Biochemical Society, Malaysian Society for Molecular Biology and Biotechnology

Past Conference Report

World Biomarkers 2017

9th World Biomarkers Congress, the World Biomarker 2017, was recently held during December 07-08, 2017 at Madrid, Spain.

World Biomarkers 2017 have taken up the scientific thoughts towards proving the importance of accurate diagnostics to be prevital towards the curing efficacy. The scientific meeting has laid path for the designing and development of research methodologies with the theme impact of “A New Era of Diagnosis and Clinical Research”. The discovery significance of the curative approach could be validated with the effectiveness of the associated clinical trials. Considering the technical integracy the Biomarkers conference embodied the research area of clinical trials and invited biopharma healthcare players. This integrated participation helped and will facilitate the technology transfer towards the recognition of biomolecular set in the form of either the specific molecule or the effective molecular pathway. The conference has tried grounding every aspect related to the Biomarkers Discovery covering the possible research areas.

This conference brought together Leading Clinical Researchers, Oncologists, Cancer Researchers, Professors, Pharmaceutical Companies, Diagnostics Companies, Students and other professionals in which many issues in Oncology & Cancer field were discussed in depth to provide up-to-date information to the world. On the other hand, the meeting provided an opportunity for networking.

The program highlights of the meeting were the eponymous lectures

·         Jianhua Luo, University of Pittsburgh, USA

·         Topolcan Ondrej, Charles University, Czech Republic

·         Wancai Yang, University of Illinois at Chicago, USA

·         Ashleigh McConnell, AMLo Biosciences Limited

Poster Evaluation Committee and the Winner:

World Biomarkers 2017 would like to acknowledge Dr.Topolcan Ondrej for his evaluation of the poster session and we are glad to congratulate Ms. Rocío Thompson-Bonilla, for receiving the Best Poster Award of the conference.

Conference series LLC takes its pleasure to thank all the Organizing Committee Members, Chairs and Co-chairs, Speakers, Students, Media Partners and all who supported the conference in every aspect for the magnificent presence at the venue.

Conference Series LLC is overwhelmed to announce the commencement of its 13th World Biomarkers Conference on November 29-30, 2018 at Dublin, Ireland.

For More details visit:

We hope to see u soon with us at World Biomarkers 2018

Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date October 8-9, 2018

Speaker Opportunity

Day 1 Day 2

Supported By

Journal of Molecular Biomarkers & Diagnosis Journal of Cancer Science & Therapy Biomarkers Journal

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by

Media partners & Collaborators & Sponsors


Media Partner


Media Partner


Media Partner


Media Partner


Media Partner


Media Partner


Media Partner


Media Partner


  • Advances In Bone Marrow Transplantation And Surgery
  • Advances In Liquid Biopsy
  • Alzheimer's Disease
  • Anal Cancer
  • Anti-cancer Drug Delivery
  • Bio Indicator
  • Biochemistry
  • Biochemistry Of Cancer
  • Biomarker Discovery
  • Biomarkers
  • Biomarkers And Diagnostics Companies
  • Biomarkers And System Biology
  • Biomarkers In Drug Development
  • Biomarkers: Validation And Verification
  • Bladder Cancer-cystectomy
  • Blastoma
  • Breast Cancer
  • Breast Cancer Biomarkers
  • Cancer Bioinformatics
  • Cancer Biology
  • Cancer Biomarkers
  • Cancer Biopsy
  • Cancer Care Team
  • Cancer Drugs And Cancer Vaccines
  • Cancer Inflammation And Immune Tolerance
  • Cancer Micro Environment
  • Cancer Nanotechnology
  • Cancer Nursing And Care
  • Cancer Pharmacology
  • Cancer Prognosis And Predictive Elements
  • Cancer Research
  • Cancer Stem Cells
  • Cancer Therapeutics
  • Cardiovascular Disease
  • Cell Biology
  • Cell Free Biomarkers
  • Cell Signalling
  • Clinical Application For Biomarkers
  • Clinical Pathology
  • Clinical Therapeutics
  • Clinical Trials And Case Report
  • Colorectal Adenoma And Cancer
  • Colorectal Cancer
  • Computational Oncology
  • Computer Assisted Tomography
  • Curative Cancer Treatment
  • Cytogenetic Biomarkers
  • Data Analysis
  • Diagnostics
  • Drug Designing
  • Drug Discovery
  • Economic Impact On Cancer
  • Ecotoxicology
  • Endocrine Malignancies
  • Environmental Pharmacology
  • Epigenetics
  • Etiology Of Cancer
  • Ewing Sarcoma
  • Factors Associated With Cancer Prevalence
  • Gastrointestinal Cancer Immunotherapy
  • Gene Markers
  • Genetics
  • Geology And Astrobiology
  • Global Market For Cancer Treatments
  • Gynaecologic Oncology
  • Head And Neck Cancers
  • Hepatocellular Carcinoma
  • Hereditary Cancers
  • Imaging Biomarker
  • Immunological Disorders
  • Immunology
  • Immunotherapy
  • Internal Medicine
  • Juvenile Myelomonocytic Leukemia (JMML)
  • Lumpectomy
  • Lung Cancer Biomarkers
  • Medical Imaging
  • Metabolite
  • Metastasis
  • Molecular Biology
  • Molecular Biomarkers
  • Molecular Epidemiology Of Cancer
  • Molecular Modelling
  • Molecular Pathology
  • Molecular Structure
  • Nanoparticles In Cancer Therapy
  • Neuro Oncology
  • Neurological Disorders
  • Non-Hodgkin Lymphoma
  • Novel Approaches To Cancer Therapeutics
  • Oncology And Radiology
  • Oncology Case Reports
  • Organ Based Cancers
  • Oxidative Stress Biomarkers
  • Palliative Cancer Treatment
  • Pathology
  • Pathophysiology Of Cancer
  • Pediatric Oncology
  • Personalized Medicine
  • Pharmacogenomics
  • Pharmacology
  • Predictive Cancer Biomarkers
  • Prognostic Biomarkers
  • Prostaglandins
  • Prostate Cancer Biomarkers
  • Psychology
  • Remission
  • Renal Cell Carcinoma
  • Saliva Testing
  • Serum Tumour
  • Sponge Biomarkers
  • Squamocellular Carcinoma Blood Disorders
  • Therapeutics
  • Translational Research
  • Tumor Markers
  • Tumor Virology
  • Types Of Biomarker And Biomarkers
  • Types Of Cancers
  • Urinary Biomarkers
  • Urothelial Carcinoma-associated-1
  • Veterinary Hematology